


# CLAIMS

1. A compound represented by formula (I)



wherein  $R^1$  and  $R^2$  each independently represents a hydrogen atom, C1-8 alkyl, a halogen atom, C1-4 alkoxy, nitro, trihalomethyl, trihalomethoxy, trihalomethylthio, cyano, C1-4 alkylthio or  $NR^7R^8$ , in which  $R^7$  and  $R^8$  each independently represents a hydrogen atom or C1-4 alkyl;

$R^3$  represents C1-8 alkyl which may be substituted with a 1-3 halogen atom(s) or phenyl;

$R^4$  represents a hydrogen atom or C1-8 alkyl;

$R^5$  and  $R^6$  each independently represents a hydrogen atom or C1-4 alkyl, or  $R^5$  and  $R^6$  may be together with their neighboring carbon atom to form a carbocyclic ring;

X represents a sulfur atom, an oxygen atom or a nitrogen atom which may have a substituent(s);

ringA represents a cyclic group which may have a substituent(s),

a salt thereof, or a solvate thereof or a prodrug thereof.

2. The compound according to claim 1, wherein the cyclic group represented by ringA is 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 4-phenylpiperidin-1-yl, 4-phenylpiperazin-1-yl, 1,3-dihydro-2H-isoindole-2-yl, 4-(4-chlorophenyl)piperazin-1-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

3. The compound according to claim 2, wherein the cyclic group represented by ringA is 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

4. The compound according to claim 1, wherein the compound is

- (1) [3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,
- (2) [3-(2-{5-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,
- (3) [3-(2-{5-ethyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,
- (4) [3-(2-{5-isopropyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,
- (5) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,
- (6) [3-(2-{5-ethyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,
- (7) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,
- (8) [2-fluoro-3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,
- (9) (2-fluoro-3-{2-[5-methyl-2-(4-phenylpiperidin-1-yl)-1,3-thiazol-4-yl]ethoxy}phenyl)acetic acid,
- (10) (3-{2-[5-methyl-2-(4-phenylpiperazin-1-yl)-1,3-thiazol-4-yl]ethoxy}phenyl)acetic acid,
- (11) (3-{2-[2-(1,3-dihydro-2H-isoindole-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-2-fluorophenyl)acetic acid,

(12) [3-(2-{2-[4-(4-chlorophenyl)piperazin-1-yl]-5-methyl-1,3-thiazol-4-yl}ethoxy)-2-fluorophenyl]acetic acid or

(13) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid.

5. A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, a salt thereof, or a solvent thereof or a prodrug thereof.

6. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a preventive and/or therapeutic agent for a PPAR-mediated disease.

7. The pharmaceutical composition according to claim 6, wherein PPAR is PPAR  $\delta$ .

8. The pharmaceutical composition according to claim 7, wherein PPAR  $\delta$ -mediated disease is hyperlipidemia or adiposity.

9. A medicament comprising the compound represented by formula (I) according to claim 1, a salt thereof, or a solvent thereof or a prodrug thereof and one kind or more kinds selected from a MTP inhibitor, a HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a fibrate drug, an ACAT inhibitor, a 5-lipoxygenase inhibitor, a cholesterol absorption inhibitor, a bile acid absorption inhibitor, a Na<sup>+</sup>/bile acid transporter inhibitor, LDL receptor activator, LDL receptor expression enhancer, a pancreatic lipase inhibitor, a probucol formulation, a nicotine acid formulation and a cholesterol ester transporter protein inhibitor.

10. A method for prevention and/or treatment for PPAR-mediated disease in a mammal, which comprises administering to a mammal an effective amount of a compound represented by formula (I) according to claim 1, a salt thereof, or a solvent thereof or a prodrug thereof.

11. Use of a compound represented by formula (I) according to claim 1, a salt thereof, or a solvent thereof or a prodrug thereof for preparing a preventive and/or therapeutic agent for PPAR-mediated disease.